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Clopidogrel resistance has been introduced recently
to refer to treatment failure in some individuals
received standard clopidogrel therapy [1]. This
phenomenon has encountered all who have tested
clopidogrel efficacy by platelet aggregometry. 
Recently, Dziewierz et al., have discussed the issue
of the „inter-individual variability in response to
clopidogrel in patients with coronary artery disease”
[2]. Their results were in agreement with many
published data in the field, which show 10 to 30%
prevalence of clopidogrel resistance in the patients
undergoing elective coronary artery stenting [3, 4].
Here we would like to emphasis on the metod used
and the interpretation of clopidogrel resistance, in
patient group reviewed by Dziewierz and associates. 
First, it is well known, that clopidogrel metabolites
are selective and irreversible antagonist of the ADP
receptor P2Y12 [5] and mutations in the P2Y12 gene
are associated with a congenital bleeding disorder and
any abnormality in the platelet response to ADP
resembling that induced by thienopyridines [6]. In this
context, ADP seems to be the most appropriate
aggregating agent to test the clopidogrel antiplatelet
effects. However, ADP activates platelets aggregation
through 3 independent receptors. Thus, use of ADP
activation via different ADP receptors is debatable,
given the fact that the relative contribution of ADP
independent receptors in platelet activation was not
fully studied to date. Classical pharmacological
parameters such as receptor up-regulation and/or
changes in receptor sensitivity/threshold for other
ADP receptors (e.g. P2Y1) are all theoretically possible
when the counter receptor P2Y12 function had been
blocked by saturating concentrations of specific
antagonists as clopidogrel. Therefore, ADP induced
platelet aggregation may not be the most suitable test
to measure the individual response to clopidogrel. 
The inhibitory effect of ADP acting selectively via
P2Y12 receptor decreases PGE1-dependent cell
signalling via cAMP-dependent phosphorylation of
VASP [7]. Thus measurement of the extent of ADP-
induced inhibition of adenylyl cyclase, or VASP
phosphorylation will be more appropriate biomarkers
to evaluate clopidogrel resistance. Aleil et al. have
evaluated the flow cytometric analysis of intraplatelet
VASP phosphorylation method recently [8]. They
conclude that the phosphorylation of VASP is
selectively dependent on the level of activation of
platelet P2Y12 receptor and therefore it could be used
as a specific test to evaluate the efficacy of clopidogrel
treatment and detecion of clopidogrel resistance [8]. 
Second, so far, no clean definition for clopidogrel
resistance is commonly accepted. Studies have shown
a dose and time dependent variability in response to
clopidogrel treatment as measured by optical platelet
aggregometry. In Dziewierz et al. study, clopidogrel
resistance were defined as ≤10% reduction in platelets
aggregation in response to 20 µmol/L ADP 24 hours
after clopidogrel treatment compared with
pretreatment values. It is worth to note that (1) Using
the same definition and similar patient population,
Gurbelet et al. reported clopidogrel resistance in 63% of
patients at 2 hours, 31% at 5 days, and 15% at 30 days
[9]. However, in most patients, the 30-day inhibitory
response from clopidogrel was predicted by the 5-day
response [4]. Therefore, 24 hours might not be enough
to evaluate clopidogrel resistance. (2) In a study
conducted by Muller and asociates, it was found that
to 5 µmol/L ADP, 5% were nonresponders and 9% were
semiresponders, and to 20 µmol/L ADP, 11% were
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nonresponders and 26% were semiresponders [4]. This
study highlights the discrepancy of the results obtained
using high and low ADP concentrations in evaluating
clopidogrel resistance. However, most of the recent
studies combine both low and high ADP concentrations
in evaluating clopidogrel resistance. 
Third, clopidogrel resistance is measured as
a percentage of decreased platelet aggregation
response ex vivo to ADP after clopidogrel treatment
compared to pretreatment. This relative value is
critically dependent on the pre- and posttreatment
platelet reactivity. It is known that elective coronary
stenting show an increase in platelet reactivity, not
all patients exhibited high platelet reactivity [10].
Furthermore, it has been shown that clopidogrel
responsiveness after the standard regimen for
coronary stenting is dependent on the pretreatment
reactivity [3, 11]. Most of the patients with high
pretreatment platelet reactivity remainded the most
reactive at 24 hours after treatment [3] and despite
being more responsive to clopidogrel, patients with
moderate reactivity posttreatment [11]. Therefore,
evaluating clopidogrel resistance alone might
overestimate the risk for stent cardiovascular events
in nonresponders with low pretreatment reactivity
and underestimate the risk in those responders who
remain with high posttreatment platelet reactivity. 
In conclusion, clopidogrel resistance could be
evaluated more accurately by measuring the
phosphorylation of VASP rather than classical
measurement of platelet aggregation in response to
ADP. Measuring platelet reactivity might be as important
as measuring the responsiveness to clopidogrel per se in
evaluating the risk of cardiovascular events in patients
undergoing coronary artery stenting and/or other
interventional procedures. 
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We are thankful to Dr Almsherqi and his colleagues
for their interest in our study and their comments
concerning clopidogrel resistance identification and
interpretation [1]. However, clarification of several
important issues related to this topic are still needed,
especially from the clinician’s point of view. 
First, the aim of our study was to assess usefulness
of simple, rapid whole blood platelet function assay
(Plateletworks Aggregation Kits, Helena Laboratories,
US) in early identification of incidence of clopidogrel
resistance [1]. Early identification of non-responders may
allow to optimise antiplatelet therapy administered
during percutaneous coronary intervention procedures,
especially in acute coronary patients, by addition, for
example, of intravenous glycoprotein IIb/IIIa inhibitors
which can achieve superior platelet inhibition in
comparison to clopidogrel alone [2, 3]. 
The VASP phosporylation state method, mentioned
by Dr Almsherqi, is one of many platelet function tests
which can be applied to cardiovascular disease as a way
to predict clinical outcomes and to monitor effects of
antiplatelet drugs [4-6]. We agree that it could be used as
a specific test to evaluate the efficacy of clopidogrel
treatment. However, this method has several limitations
(time-consuming sample preparation, expensiveness,
requirement of flow cytometer and experienced operator)
which reduces its usefulness in everyday clinical practice,
especially in diagnosis and treatment of acute coronary
patients [4]. Reports about prediction of clinical outcomes
using this method are also limited [4, 5]. 
The Plateletworks assay, unlike VASP phosporylation
state, is a simple, point-of-care, time-saving method
based on a standard automated cell counter [4, 7].
Therefore it can be used in hospitals and catheterization
laboratories offering 24/7 service to monitor the effect of
platelet inhibitors during percutaneous coronary
interventions, especially in acute coronary patients.
Others have shown that results obtained by this method
correlate well with the results obtained by the use of
optical aggregometry and other whole blood platelet
function assays [7, 8]. The Plateletworks Aggregation Kits
method is also able to determine combined antiplatelet
treatment effects (including glycoprotein IIb/IIIa
antagonists) in total [4]. Therefore, it may be important
for predicting long-term clinical outcome [9]. 
We agree that, so far, there is not a standardised
definition of clopidogrel resistance, nor clinically
confirmed platelet aggregation inhibition cut-off value to
identify non-responders to clopidogrel [10]. In our study
we used the most popular definition proposed by Gurbel
et al. [11]. On the other hand, Serebruany et al. has
recently shown, in a cohort of 544 individuals, a normal,
bell-shaped distribution of response to clopidogrel [12].
In this paper platelet response to clopidogrel was defined
as follows: hypo-responders (two standard deviations
below the mean), hyper-responders (two standard
deviations above the mean); and the remaining subjects
were defined as normal responders [12]. This definition
seems to be more physiologic than that based on
arbitrary platelet aggregation inhibition cut-off value,
because the optimal level of platelet aggregation
inhibition to prevent cardiovascular events may vary in
different patients’ subsets. 
Our study focused on early effects of clopidogrel
treatment (within 24 hours), which may be crucial for
predicting cardiovascular events during follow-up [1].
We fully agree that 24 hours may not be enough for
definitive confirmation of non-response to clopidogrel
[13]. Regardless, our paper supports that early
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identification (6 hours from the first dose of
clopidogrel) of non-responders is possible and clinically
feasible. The response to therapy measured at 6 hours
correlated well with that assessed at 24 hours [1].
Others have documented that platelet aggregation
inhibition examined at 24 hours highly correlates with
that measured 5 or 30 days from the initiation of
clopidogrel treatment [13]. 
It is well known that baseline platelet activity before
administration of a loading dose of clopidogrel seems
to be an important factor determining response to
treatment. Also, in many studies, an increase in platelet
activity after coronary stenting was observed [11]. To
avoid influence of coronary stenting on platelet
inhibition measurements and achieved results, in our
study all blood samples were taken before
percutaneous coronary intervention [1]. 
In conclusion, results of many studies demonstrate
a wide range of responsiveness to clopidogrel in patients
with cardiovascular diseases [1, 5, 11, 12, 14, 15]. To date,
there are only a few small trials that have explored the
clinical relevance of an inadequate response to
clopidogrel [5, 14, 15]. Large scale clinical trials to correlate
platelet function measurements with clinical outcomes
are still needed. If these measurements will correspond to
the risk of cardiovascular complications during follow-up,
rather simple methods of platelet function testing may be
useful in every day clinical practice for the optimisation of
the antiplatelet therapy in the future. 
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